Controversy Pullback Offers Good Entry Point For Mylan


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Argus’ Jacob Kilstein believes generic drug companies would “continue to benefit from the increased focus on cost-effective healthcare.”

Kilstein maintains a Buy rating and a $55 price target on Mylan NV (NASDAQ: MYL).

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Attractive Entry Point

The stock has declined 17 percent over the past month, driven by negative publicity associated with Mylan’s sharp price hike for EpiPen.

However, the analyst believes this pullback offers an attractive entry point.

The EpiPen Price Hike


Wall Street Vet Reveals $9 Options Secret

Tired of tiny stock gains? This 40-year insider is spilling the beans on how to turn small investments into 600% returns. Get his proven options strategy in a FREE webinar.—Register now – seats are limited!


The company raised the price of a pack of two EpiPen shots to $600, a sharp increase from the $100 it was priced at when the product was acquired in 2007.

“Mylan has responded to the public criticism in a number of ways. It pointed out that most patients pay less than $100 out-of-pocket because insurance covers most of the cost, and that many patients and schools had access to free EpiPens,” Kilstein mentioned.

The company also offered $300 coupons to some of the users, while on August 29, Mylan announced that it launch a generic EpiPen in the near future, priced at $300.

“While the generic product will cannibalize branded sales, it should help to ward off competition from… other potential generic manufacturers, and give Mylan the advantage of being first in the generic EpiPen market,” the analyst explained.

In fact, if the company were to launch its generic version within the next month, Mylan would have an 18-month window where there would be no competition.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Posted In: Analyst ColorBiotechLong IdeasNewsHealth CareReiterationAnalyst RatingsMoversTrading IdeasGeneralArgusEpiPenJacob Kilstein